Immunologist Expert Dr. Paul Peter Tak Joins GoodCell as Strategic Advisor
Company’s leadership continues to expand in its vision to shape the future of personalized health as today’s science becomes tomorrow’s medicine.
Waltham, MA – September 29, 2021 – GoodCell, a medically-actionable service to identify, track and respond to health risks, is expanding its strategic advisors with the appointment of Paul Peter Tak, M.D., Ph.D. Dr. Tak is a world-renowned immunologist, drug developer, pharmaceutical CEO and entrepreneur with over 25 years of experience in the pharmaceutical industry.
Cellular therapeutics and treatments are being rapidly introduced in today’s healthcare market and GoodCell’s leadership is on a mission to empower people to live longer, healthier lives by using the power of their blood for dynamic and comprehensive diagnostics and ultimately life-saving cellular therapies utilizing the Company’s personal biobanking, genetic testing and health screening tools.
“The GoodCell team is committed to innovation in the area of blood-based diagnostics in order to expand and enhance our services,” said Chris Garcia, Chief Executive Officer, GoodCell. “As a leading expert in immunology, Dr. Tak’s insights and guidance will be invaluable to our robust IP development of diagnostic tools to cover a wider range of risk identification and monitoring.”
“We’re thrilled to have Dr. Tak join GoodCell’s leadership team,” added Trevor Perry, President, GoodCell. “I am confident his academic, pharmaceutical and therapeutics expertise will be of great value as we continue to seek to expand the products and services we offer.”
In addition to serving as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC), Dr. Tak was Clinical Associate Professor of Medicine at the University of California San Diego. He also served as Senior Vice President, Chief Immunology Officer, and Global Development Leader at GlaxoSmithKline (GSK), he is a co-founder of Sitryx and was previously President and CEO of Tempero Pharmaceuticals and Venture Partner at Flagship Pioneering. Dr. Tak is currently President and CEO of Candel Therapeutics, which in July announced the pricing of its Initial Public Offering (IPO) and sits on the board of several biotech companies.
“Genetic data and biological information become powerful when you think about the significance of being able to determine predispositions to disease, preserve your healthiest cells for future medical treatments while tracking changes to health over time, and ultimately developing precision medicine,” said Paul Peter Tak, M.D., Ph.D. “GoodCell is a unique offering at the leading edge of science, and I’m excited to support the company at this stage of growth.”
GoodCell’s vision is to give every person control over their health by providing access to a science-backed, technology-forward platform that decodes the common language of our cells and extends the quality of life for individuals, their families and all of humankind. The company’s platform uniquely combines personal biobanking, diagnostics and data to provide individuals and their families the ability to securely test, track and respond to health risks, while enabling the scientific community to advance diagnostics and drug development at scale to create next-generation safeguards for global health. Driven by mounting evidence in support of cellular therapy and united in the belief that you should be empowered to take control of your health, GoodCell is led by a founding team of science and technology innovators with a diverse set of medical research. Learn more at: www.goodcell.com.